These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25420693)

  • 1. Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
    Kondo T; Nakazawa H; Oya M; Kimura G; Fujii Y; Hatano T; Kawata N; Kume H; Morita M; Nakajima K; Ohno Y; Okegawa T; Takahashi S; Wakumoto Y; Horie S; Yamaguchi R; Saito K; Murakami M
    Jpn J Clin Oncol; 2015 Mar; 45(3):274-80. PubMed ID: 25420693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
    Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
    Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
    Jäger D; Ma JH; Mardiak J; Ye DW; Korbenfeld E; Zemanova M; Ahn H; Guo J; Leonhartsberger N; Stauch K; Böckenhoff A; Yu J; Escudier B
    Clin Genitourin Cancer; 2015 Apr; 13(2):156-64.e1. PubMed ID: 25444666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.
    Zhang HL; Qin XJ; Wang HK; Gu WJ; Ma CG; Shi GH; Zhou LP; Ye DW
    Oncotarget; 2015 Nov; 6(34):36870-83. PubMed ID: 26472104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
    Bracarda S; Porta C; Boni C; Santoro A; Mucciarini C; Pazzola A; Cortesi E; Gasparro D; Labianca R; Di Costanzo F; Falcone A; Cinquini M; Caserta C; Paglino C; De Angelis V
    Eur Urol; 2013 Feb; 63(2):254-61. PubMed ID: 22964169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
    Omae K; Kondo T; Kennoki T; Takagi T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
    Int J Clin Oncol; 2016 Feb; 21(1):126-32. PubMed ID: 26163345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.
    Tanigawa G; Kawashima A; Yamaguchi S; Nishimura K; Miyoshi S; Kajikawa J; Meguro N; Yosioka T; Oka T; Hara T; Takayama H; Nonomura N;
    Jpn J Clin Oncol; 2011 Nov; 41(11):1265-70. PubMed ID: 21965163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
    Tafreshi A; Thientosapol E; Liew MS; Guo Y; Quaggiotto M; Boyer M; Davis ID
    Asia Pac J Clin Oncol; 2014 Mar; 10(1):60-5. PubMed ID: 24152417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
    Zhang Y; Li Y; Cai Y; Wang K; Li H
    Cell Oncol (Dordr); 2016 Feb; 39(1):15-21. PubMed ID: 26597814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 15. Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
    Miyake H; Miyazaki A; Imai S; Harada K; Fujisawa M
    Target Oncol; 2016 Apr; 11(2):175-82. PubMed ID: 26341668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma.
    Iacovelli R; Verzoni E; Grassi P; Farcomeni A; de Braud F; Procopio G
    Tumori; 2014; 100(6):e282-5. PubMed ID: 25688511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
    Gore ME; Jones RJ; Ravaud A; Kuczyk M; Demkow T; Bearz A; Shapiro J; Strauss UP; Porta C
    BJU Int; 2017 Jun; 119(6):846-853. PubMed ID: 27981711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
    Hainsworth JD; Waterhouse DM; Penley WC; Shipley DL; Thompson DS; Webb CD; Anthony Greco F
    Cancer Invest; 2013 Jun; 31(5):323-9. PubMed ID: 23614653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
    Porta C; Procopio G; Cartenì G; Sabbatini R; Bearz A; Chiappino I; Ruggeri EM; Re GL; Ricotta R; Zustovich F; Landi L; Calcagno A; Imarisio I; Verzoni E; Rizzo M; Paglino C; Guadalupi V; Bajetta E
    BJU Int; 2011 Oct; 108(8 Pt 2):E250-7. PubMed ID: 21599821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.